- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Hypera SA (HYPE3)
The Hypera share price today is 21.27, view BVMF HYPE3 stock exchange data. Track the latest Hypera share price with real-time updates on HYPE3 stock performance including market cap, day range, 52-week range and dividend yield. Access HYPE3 charts, earnings dates and analyst estimates to support your investment decisions.
21.27
-0.38(-1.76%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.22
22.20
52 wk Range
19.71
27.79
Earnings results expected in 3 days
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
21.2222.20
52 wk Range
19.7127.79
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.13%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(5.13%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
HYPE3 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
29.15
Upside
+37.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
- HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update
- Investing.com
Pro - HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
HYPERMARCAS ON NM receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
12 Buy
3 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 29.15
(+37.03% Upside)
Earnings
Latest Release
28-04-2026
EPS / Forecast
0.49 / 0.50
Revenue / Forecast
2.02B / 2.01B
Compare HYPE3 to Peers and Sector
Metrics to compare | HYPE3 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHYPE3PeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.9x | 9.7x | −0.4x | |
PEG Ratio | 0.08 | −0.28 | 0.00 | |
Price/Book | 1.1x | 1.5x | 2.6x | |
Price / LTM Sales | 1.7x | 1.6x | 3.0x | |
Upside (Analyst Target) | 36.3% | 47.7% | 56.0% | |
Fair Value Upside | Unlock | 13.5% | 9.1% | Unlock |
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Hypera (HYPE3) Share Price Today?
The Hypera share price today is 21.27.
What is the current Hypera (HYPE3) share price and day range?
As of 03-08-2026, the Hypera share price is 21.27, with a previous close of 21.27. The share price has ranged from 21.22 to 22.20 today, while the 52-week range spans from 19.71 to 27.79.
What Is the Hypera Market Cap?
As of today, Hypera market cap is 14.96B.
Does Hypera Pay Dividends? What's The Current Dividend Yield?
The Hypera dividend yield is 5.13%.
What Is the Hypera (HYPE3) Share Price Target?
The average 12-month share price target for Hypera is 29.15, with a high estimate of 35 and a low estimate of 24. 12 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +37.03% Upside potential.
What Is Hypera's Earnings Per Share (TTM)?
The Hypera EPS (TTM) is 2.63.
When Is the Next Hypera Earnings Date?
Hypera will release its next earnings report on 06-08-2026.
From a Technical Analysis Perspective, Is HYPE3 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Hypera Trade On?
Hypera is listed and trades on the B3 Stock Exchange.
What Is the Stock Symbol for Hypera?
The stock symbol for Hypera is "HYPE3."
How Many Times Has Hypera Stock Split?
Hypera has split 2 times.
How Many Employees Does Hypera Have?
Hypera has 10564 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.